PLC Systems Announces First Distribution Agreement in Spain for RenalGuard(R)
Posted on: Monday, 4 May 2009, 07:00 CDT
PLC's President and Chief Executive Officer,
PLC received the CE Mark Certificate for the RenalGuard System in late
About PLC Systems Inc.
PLC Systems Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Headquartered in
This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may not receive necessary regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn, we may be unable to raise sufficient funds in the future to implement our business plan and/or commence our planned U.S. clinical trial for RenalGuard, the current CCM clinical trial and the planned future U.S. clinical trial for RenalGuard as a safe and effective CIN prevention device may not be completed in a timely fashion if at all, or, if these clinical trials are completed, they may not produce clinically significant or meaningful results, the RenalGuard product may not be commercially accepted, operational changes, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in the "Forward Looking Statements" section of our Annual Report on Form 10-K for the year ended
PLC Systems, PLC Medical Systems, PLC, CO2 Heart Laser, RenalGuard and RenalGuard System are trademarks of PLC Systems Inc.
Contact: Mary T. Conway Conway Communications 617-244-9682 mtconway@att.netSOURCE PLC Systems Inc.
Source: PR Newswire
Related Articles
- Cardica Announces Publication of Pivotal PAS-Port(R) Proximal Anastomosis System Clinical Trial Results
- David Feldman, M.D. Appointed Co-Principal Investigator of DuraHeart(TM) Left Ventricular Assist System U.S. Clinical Trial
- Threshold Pharmaceuticals Initiates a Clinical Trial Evaluating TH-302 in Patients With Soft Tissue Sarcoma
- Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
- Cytokinetics Announces Positive Results From an Interim Analysis of an Ongoing Phase IIa Clinical Trial of CK-1827452 in Patients With Stable Heart Failure
- Cytokinetics Announces the Initiation of a Phase I Clinical Trial for GSK-923295
- Cytokinetics Announces Data From Phase II Clinical Trial of Ispinesib in Breast Cancer
- Cytokinetics Announces the Presentation of Clinical Trials Data at the 2007 Annual Meeting of the American Society of Clinical Oncology
- TAXUS II Clinical Trial Follow-Up Data Demonstrates Excellent Long-Term Outcomes at Four Years
- Pro-Pharmaceuticals Announces Dosing of Cancer Patient With DAVANAT/5-FU in a Phase II Clinical Trial at Medical Oncology & Hematology, P.C.
 |
 |
User Comments (0)
RSS Feeds